| Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming L Lindbom, J Ribbing, EN Jonsson Computer methods and programs in biomedicine 75 (2), 85-94, 2004 | 751 | 2004 |
| Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programming L Lindbom, J Ribbing, EN Jonsson Computer methods and programs in biomedicine 75 (2), 85-94, 2004 | 751 | 2004 |
| Power, selection bias and predictive performance of the population pharmacokinetic covariate model J Ribbing, E Niclas Jonsson Journal of pharmacokinetics and pharmacodynamics 31, 109-134, 2004 | 176 | 2004 |
| The lasso—a novel method for predictive covariate model building in nonlinear mixed effects models J Ribbing, J Nyberg, O Caster, EN Jonsson Journal of pharmacokinetics and pharmacodynamics 34 (4), 485-517, 2007 | 97 | 2007 |
| A model for glucose, insulin, and beta‐cell dynamics in subjects with insulin resistance and patients with type 2 diabetes J Ribbing, B Hamrén, MK Svensson, MO Karlsson The Journal of Clinical Pharmacology 50 (8), 861-872, 2010 | 45 | 2010 |
| A pharmacokinetic comparison of anrukinzumab, an anti‐IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients F Hua, J Ribbing, W Reinisch, F Cataldi, S Martin British journal of clinical pharmacology 80 (1), 101-109, 2015 | 42 | 2015 |
| Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 second X Wang, D Shang, J Ribbing, Y Ren, C Deng, T Zhou, F Guo, W Lu European journal of clinical pharmacology 68, 1157-1166, 2012 | 16 | 2012 |
| Characterizing Systemic Exposure of Inhaled Drugs: Application to the Long-Acting β2-Agonist PF-00610355 PM Diderichsen, E Cox, SW Martin, A Cleton, J Ribbing Clinical pharmacokinetics 52 (6), 443-452, 2013 | 15 | 2013 |
| A model‐based longitudinal meta‐analysis of FEV1 in randomized COPD trials J Korell, SW Martin, MO Karlsson, J Ribbing Clinical Pharmacology & Therapeutics 99 (3), 315-324, 2016 | 13 | 2016 |
| Translating pharmacometrics to a pharmacoeconomic model of COPD JF Slejko, RJ Willke, J Ribbing, P Milligan Value in Health 19 (8), 1026-1032, 2016 | 12 | 2016 |
| Longitudinal FEV1 dose–response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease JC Nielsen, MM Hutmacher, A Cleton, SW Martin, J Ribbing Journal of pharmacokinetics and pharmacodynamics 39 (6), 619-634, 2012 | 12 | 2012 |
| Predicted heart rate effect of inhaled PF‐00610355, a long acting β‐adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease PM Diderichsen, E Cox, SW Martin, A Cleton, J Ribbing British Journal of Clinical Pharmacology 76 (5), 752-762, 2013 | 11 | 2013 |
| Covariate Model Building in Nonlinear Mixed Effects Models J Ribbing Acta Universitatis Upsaliensis, 2007 | 5 | 2007 |
| A phase II, randomised, placebo controlled trial of 12 weeks treatment with an oral p38 inhibitor in patients with COPD on a background of ICS/LABA R Fogel, K Shields, J Christensen, J Ribbing, G Langdon, ... European Respiratory Journal 42 (Suppl 57), 2013 | 4 | 2013 |
| Assessing the therapeutic benefit of a new inhaled QD LABA through population PK-safety & efficacy modelling J Ribbing, GL Li, E Van Schaick, L Harnisch ERS, Vienna, Austria, 2009 | 4 | 2009 |
| Population repeated time‐to‐event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and … RJ Svensson, J Ribbing, N Kotani, M Dolton, S Vadhavkar, D Cheung, ... CPT: Pharmacometrics & Systems Pharmacology 10 (10), 1221-1235, 2021 | 3 | 2021 |
| Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies J Ribbing, AC Hooker, EN Jonsson Journal of Pharmacokinetics and Pharmacodynamics 35, 117-137, 2008 | 3 | 2008 |
| Cross Model Validation As A Tool For Population Pharmacokinetic/Pharmacodynamic Covariate Model Building J Ribbing, EN Jonsson PAGE 10 (2001), 2001 | 3 | 2001 |
| Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis A Moein, T Lu, S Jönsson, J Ribbing, N Kassir, W Zhang, G Sperinde, ... CPT: Pharmacometrics & Systems Pharmacology 11 (9), 1244-1255, 2022 | 2 | 2022 |
| Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis N Kassir, R Zhu, A Moein, J Langenhorst, J Ribbing, R Zhang, MT Tang, ... CPT: Pharmacometrics & Systems Pharmacology 11 (9), 1234-1243, 2022 | 2 | 2022 |
